Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1995;22(6):349-52.
doi: 10.1007/BF00296873.

Expression of mdm-2 and p53 protein in transitional cell carcinoma

M Barbareschi  1 , S Girlando, G Fellin, U Graffer, L Luciani, P Dalla Palma
Affiliations

Expression of mdm-2 and p53 protein in transitional cell carcinoma

M Barbareschi et al. Urol Res. 1995.

Abstract

Amplification of the mdm-2 gene and overexpression of the mdm-2 protein might inactivate p53 function, and may have prognostic relevance. The present paper investigated the immunohistochemical overexpression of the mdm-2 and p53 proteins in 25 biopsy specimens of transitional cell bladder carcinomas (10 pT1 and 15 pT2 or higher stages). Five cases (20%) showed strong mdm-2 protein immunoreactivity in more than 5% of the tumor cells; 14 cases (56%) showed p53 immunoreactivity in more than 20% of the cells, and were considered as overexpressing p53 protein. Four of the five cases with strong mdm-2 immunoreactivity did not show p53 overexpression, and 13 of the 14 cases with p53 overexpression did not show mdm-2 immunoreactivity. Our data are consistent with the hypothesis that p53 overaccumulation (and hence possible p53 gene mutation) or mdm-2 overexpression (and hence possible mdm-2 gene amplification) may mirror two different and possibly complementary gene alterations, which might finally interfere with the control of cell proliferation and apoptosis. In this perspective, evaluation of the combined mdm-2/p53 protein phenotype in human bladder carcinomas could have prognostic relevance and give us better prognostic information than evaluation of the p53 protein alone.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Nature. 1992 Jul 2;358(6381):80-3 - PubMed
    1. FASEB J. 1993 Jul;7(10):855-65 - PubMed
    1. Cancer Res. 1993 Jan 1;53(1):16-8 - PubMed
    1. Oncogene. 1993 Oct;8(10):2683-90 - PubMed
    1. Cancer Res. 1993 May 15;53(10 Suppl):2231-4 - PubMed

MeSH terms